Table 2 Clinicopathological variables related to DNA ploidy in curettage specimens from 785 patients with endometrial cancer, classified as either diploid or non-diploid (aneuploid, tetraploid, and polyploid)

From: DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer

Variables Category Diploid Non-diploid P -value
Age at primary treatment <66 Years 309 80.3% 76 19.7%  
  ≥66 Years 256 64.0% 144 36.0% <0.001
Information available preoperatively
Curettage histology classificationa Low risk 499 83.2% 101 16.8%  
  High risk 63 35.0% 117 65.0% <0.001
Information available postoperatively
FIGO stage (2009) I/II 503 75.5% 163 24.5%  
  III/IV 62 52.1% 57 47.9% <0.001
Histological subtypeb Endometrioid 530 80.8% 126 19.2%  
(hysterectomy specimen) Non-endometrioid 35 27.6% 92 72.4% <0.001
Histological gradec Grades 1 and 2 462 83.5% 91 16.5%  
(hysterectomy specimen) Grade 3 101 44.5% 126 55.5% <0.001
Myometrial infiltrationd <50% 349 77.0% 104 23.0%  
(hysterectomy specimen) ≥50% 173 67.8% 82 32.2% 0.008
Lymph node metastasise No 381 74.4% 131 25.6%  
  Yes 38 52.8% 34 47.2% <0.001
Recurrencef No 443 76.5% 136 23.5%  
  Yes 58 57.4% 43 42.6% <0.001
  1. Abbreviation: FIGO=International Federation of Gynaecology and Obstetrics.
  2. All P-values are by Pearson’s χ2 test.
  3. aCurettage histological risk classification as either low risk (benign, hyperplasia, or endometrioid grades 1–2) or high risk (comprising non-endometrioid or endometrioid grade 3 histology). Curettage histology risk classification missing for five patients.
  4. bHistological subtype missing for two patients.
  5. cHistological grade missing for five patients.
  6. dMyometrial infiltration not available for 77 patients.
  7. eLymph node status evaluated in 584 patients.
  8. fRecurrence only evaluated in patients considered tumour free after operation (n=680).